Showing 151-160 of 1945 results for "".
Treating Dry Eye at the Molecular Level
https://modernod.com/podcasts/to-the-point/treating-dry-eye-at-the-molecular-level/36939/Jacob Lang, OD, FAAO, shares his knowledge of innovative therapies for dry eye with Jackie Garlich, OD, FAAO, and Jessilin Quint, OD, MBA, MS, FAAO. He discusses drugs in development that target pathways involved in ocular surface disease, such as reactive aldehyde species inhibitors, transient receThe Changing Landscape of Dry Eye Disease
https://modernod.com/podcasts/to-the-point/the-changing-landscape-of-dry-eye-disease/36912/In this episode of To the Point, Jackie Garlich, OD, FAAO, and Leslie O’Dell, OD, FAAO, are joined by Kelly K. Nichols, OD, MPH, PhD, FAAO, who shares her knowledge of novel dry eye therapies in the pipeline. Dr. Nichols also discusses what optometrists can look forward to in the next couple of yearMaking the Move to an Aesthetic Practice
https://modernod.com/podcasts/to-the-point/making-the-move-to-an-aesthetic-practice/36910/Hosts Jackie Garlich, OD, FAAO, and Leslie O’Dell, OD, FAAO, talk practice management strategies with guest Melanie Denton, OD, MBA, FAAO. Dr. Denton outlines the pros of earning an MBA, the steps she took in opening her practice and adding aesthetics, how to hire consultants, and general patient bePart 2: Contact Lens Business and Patient Safety in The COVID-19 Era: Redefining Normal
https://modernod.com/podcasts/the-mod-pod/part-2-contact-lens-business-and-patient-safety-in-the-covid-19-era-redefining-normal/36785/The conclusion of our two-part special episode of The MOD Pod – Contact Lens Business and Patient Safety in the COVID-19 Era: Redefining Normal. Listen to Rachael Wruble, OD, FAAO, speak with colleagues Brianna Rhue, OD, FAAO; William To, OD; and Justin Weigel, OD, about how they navigated the immedFrom MD to OD: Tips for Referring Refractive Patients
https://modernod.com/topics/cataractrefractive-surgery/from-md-to-od-tips-for-referring-refractive-patients/39152/A surgeon suggests some advice for ODs based on his perspective.Educating Patients About Refractive Solutions
https://modernod.com/podcasts/the-mod-pod/educating-patients-about-refractive-solutions/39862/In this episode, Marc R. Bloomenstein, OD, FAAO, invites Nicholas Bruns, OD, FAAO, to share advice for how to talk to patients about the pros and cons of different refractive procedures like LASIK, photorefractive keratectomy (PRK), and EVO ICL (Staar Surgical) implantation. Dr. Bruns reviews the poMake Informed Clinical Decisions About Dry Eye Treatment
https://modernod.com/podcasts/to-the-point/make-informed-clinical-decisions-about-dry-eye-treatment/36918/Jackie Garlich, OD, FAAO, and Leslie O’Dell, OD, FAAO, connect with Robert Sambursky, MD, to learn about what’s new in point-of-care testing for dry eye disease. Dr. Sambursky describes how quantitative diagnostics and follow-up testing can help optometrists provide more personalized care and show pPresbyopia Drops • Glaucoma Diagnostics • Specialty Lenses
https://modernod.com/podcasts/the-mod-pod/presbyopia-drops-glaucoma-diagnostics-specialty-lenses/36822/Rachael A. Wruble, OD, FAAO, leads off the episode with a discussion on how presbyopia-correcting drops will fit into the treatment toolbox (00:45). Daniel Epshtein, OD, FAAO, and co-author Patricia Fulmer, OD, FAAO, follow with a survey of new and next-generation technologies and devices in their pThe Near Future in Managing Dry Eye Disease
https://modernod.com/topics/corneaanterior-segment/the-near-future-in-managing-dry-eye-disease-1/36877/Cecelia Koetting, OD, FAAO, DipABO, and Marc Bloomenstein, OD, FAAO, convened to discuss the current state of ocular surface disease, including the progressive nature, patient communication and symptoms, new and upcoming therapies, and more.Get Excited for Your Patients With Dry Eye
https://modernod.com/podcasts/to-the-point/get-excited-for-your-patients-with-dry-eye/36919/Make room in your dry eye toolkit! Jackie Garlich, OD, FAAO, and Leslie O’Dell, OD, FAAO, dedicate this episode to a discussion of eagerly awaited products in the pipeline for the treatment of ocular surface disease.